Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease. Up to 40% of patients
with psoriasis will go on to develop PsA, usually within 5–10 years of cutaneous disease …

Psoriatic arthritis (PsA) is a heterogeneous disease that can involve a variety of distinct
anatomical sites including a patient's peripheral and axial joints, entheses, skin and nails …

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in
2012, but the evidence for these recommendations was only of indirect nature. These …

Background Since the publication of the European League Against Rheumatism
recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new …

Background Early intervention and tight control of inflammation optimise outcomes in
rheumatoid arthritis but these approaches have not yet been studied in psoriatic arthritis. We …

Objective To examine the efficacy of methotrexate monotherapy relative to etanercept
monotherapy and the value of combining methotrexate and etanercept for the treatment of …

Background The Disease Activity Index for Psoriatic Arthritis (DAPSA) is a valid and
discriminative tool. Definitions of disease activity states and therapeutic response are still …

Background Therapeutic targets have been defined for diseases like diabetes, hypertension
or rheumatoid arthritis and adhering to them has improved outcomes. Such targets are just …

Introduction The objective was to develop a questionnaire that can be used to calculate a
score reflecting the impact of psoriatic arthritis (PsA) from the patients' perspective: the PsA …

Objectives To assess the efficacy and safety of abatacept, a selective T-cell costimulation
modulator, in a phase III study in psoriatic arthritis (PsA). Methods This study randomised …